Brief: Biofrontera To Market Medac's Ameluz And Bf-Rhodoled In Poland

Biofrontera AG

23/07/2021 09:21

July 23 (Reuters) - BIOFRONTERA AG  B8FGn.DE :
    * SIGNED AN EXCLUSIVE LICENSE AND SUPPLY AGREEMENT FOR
MARKETING
OF BOTH AMELUZ® AND BF-RHODOLED® IN POLAND
    * MEDAC WILL MAKE AN IMMEDIATE ONE-TIME UPFRONT PAYMENT OF
EUR
50,000 TO COMPANY
    * AGREEMENT HAS A TERM OF 5 YEARS COMMENCING WITH START OF
SALES
IN POLAND
    * ADDITIONAL ONE-TIME PAYMENT OF EUR 150,000 FOLLOWING
RECEIPT OF
DRUG'S REIMBURSEMENT ELIGIBILITY FROM POLISH HEALTH INSURANCE
PROVIDERS

Source text for Eikon:  ID:nPexyFCtqa 
Further company coverage:  B8FGn.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;  +48 58 769 6600;))